MR Imaging of Myocardial Infarction

Hall C
Wednesday: 13:30 – 15:30

1593.   Preliminary Evaluation of EVP 1001-1: A New Cardiac Specific MR Contrast Agent with Optimal Kinetics for Evaluation of the Ischemic Heart, P.V. Prasad, M. Post, P. Storey, W. Li, P.R. Seoane, P.P. Harnish and R.R. Edelman, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA and Eagle Vision Pharmacuetical Corp, Chester Springs, PA, USA.
1594.   Delayed Contrast Enhancement Magnetic Resonance Imaging Identifies Acute Myocardial Infarction in Humans and Correlates with Extent of Myocardial Damage, R.B. Minton, J.M. Wilson, R. Muthupillai, M. Pereyra, A. Achari and S.D. Flamm, Texas Heart Institute, Houston, TX, USA and Philips Medical System, Best, Netherlands.
1595.   Comparison of Infarct Size Using T2 Weighted Turbo Spin-Echo MRI to Pathology in a Canine Model of Ischemic Heart Disease, S.D. Buchthal, I.M. Sträter-Knowlen, G.M. Pohost and J.A. den Hollander, University of Alabama, Birmingham, AL, USA.
1596.   Myocardial Postcontrast T1 Enhancement Corresponds to Decreased Regional FDG Activity in Patients with Multivessel Coronary Artery Disease, K. Lauerma, T. Janatuinen, H.A. Hänninen, P. Niemi, L.M. Voipio-Pulkki, L. Toivonen, J. Knuuti and H.J. Aronen, Helsinki University Central Hospital, Helsinki, Finland and PET Centre, Turku, Finland.
1597.   The Severity of Microvascular Damage Immediately Following Myocardial Infarction May Not be Sufficient to Allow Extravascular Escape of a Blood Pool Contrast Agent into the Injured Region, J. Mark, G. Dai, B. Xiang, J. Sun, J. Shen, N. Lazarow, W.G. Lindsay, R. Deslauriers and G. Tian, National Research Council Canada, Winnipeg, Manitoba, Canada; Dayton VA Medical Center, Dayton, OH, USA and University of Manitoba, Winnipeg, Manitoba, Canada.
1598.   Early In Vivo Markers of Myocardial Lesion Following Coronary Ligation in Rats, S. Lenhard, L. Clark, J. Chen, T. Schaeffer, S. Sarkar, E.H. Ohlstein, T.L. Yue and S. Chandra, SmithKline Beecham Pharmaceuticals, King of Prussia, PA, USA.
1599.   Combined 87Rb and ²³Na NMR for Imaging Infarction in Isolated Pig Hearts, V.V. Kupriyanov, G. Dai, J. Sun, O. Jilkina, Z. Luo and R. Deslauriers, National Research Council Canada and University of Manitoba, Winnipeg, Manitoba, Canada.
1600.   Infarct Size Measurement with 3D ²³Na MRI in Chronically Infarcted Rat Hearts, C. Weidensteiner, M. Horn, S. Neubauer and M. v. Kienlin, Universität Würzburg, Würzburg, Germany.
1601.   T2-Weighted MRI Predicts Functional Loss Early After Myocardial Infarction in Dogs: Comparison with Bis-Gadolinium-Mesoporphyrin Enhanced T1-Weighted MRI and Functional Data from Cine MRI, S. Dymarkowski, Y. Ni, Y. Miao, J. Bogaert, F.E. Rademakers, H. Bosmans, U. Speck, W. Semmler and G. Marchal, University Hospital KU, Leuven, Belgium and Schering AG, Berlin, Germany.
1602.   Protective Effects of Nicorandil in Reducing Myocardial Infarct Size Demonstrated by Necrosis Specific MR Contrast Media, M. Saeed, G. Lund, M.F. Wendland, H-J. Weinmann and C.B. Higgins, University of California, San Francisco, CA, USA and Schering AG, Berlin, Germany.

Return to ISMRM program